Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2011) 55(5) (1041–1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047))

Wei Tien Tai, Ann Lii Cheng, Chung Wai Shiau, Hsiang Po Huang, Jui Wen Huang, Pei Jer Chen*, Kuen Feng Chen

*Corresponding author for this work

Research output: Contribution to journalComment/debate

1 Scopus citations

Abstract

After careful examination of the raw data included in this manuscript, we found that the Western blots of the internal control, actin, in Fig. 3B and C were the same as the Fig. 2D. We have corrected this error in the revised Fig. 3 below. In addition, the expression level of SOCS-1 and SOCS-3 in Fig. 4E should be under sorafenib 5 μM and 10 μM treatments, rather than sorafenib and SC-1 treatment. The corrected version of Fig. 4 is also included below. The authors would like to apologise for these errors and for any inconvenience this may have caused.

Original languageEnglish
Pages (from-to)666-668
Number of pages3
JournalJournal of Hepatology
Volume66
Issue number3
DOIs
StatePublished - 1 Mar 2017

Fingerprint

Dive into the research topics of 'Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2011) 55(5) (1041–1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047))'. Together they form a unique fingerprint.

Cite this